National Health (Price and Special Patient Contribution) Amendment Determination 2016 (No. 1) (PB 2 of 2016) (Cth)

PB 2 of 2016

National Health (Price and Special Patient Contribution) Amendment Determination 2016 (No. 1)

National Health Act 1953

I, JULIANNE QUAINE, First Assistant Secretary (Acting), Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Determination under section 85B of the National Health Act 1953.

Dated 25 January 2016

JULIANNE QUAINE

First Assistant Secretary (Acting)

Pharmaceutical Benefits Division

Department of Health

1          Name of Instrument

(1)        This Instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2016 (No. 1).

(2)        This Instrument may also be cited as PB 2 of 2016.

2          Commencement

This Instrument commences on 1 February 2016.

3          Amendment of the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010)

Schedule 1 amends the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010).

Schedule 1     Amendments

[1]Schedule 1, entry for Cephalexin in the form Capsule 250 mg (anhydrous)

omit from the column headed “Claimed Price”:          3.93        substitute:             4.31

[2] Schedule 1, entry for Cephalexin in the form Capsule 500 mg (anhydrous)

omit from the column headed “Claimed Price”:          5.99        substitute:             6.55

[3] Schedule 1, entry for Cephalexin in the form Granules for oral suspension 125 mg per 5 mL, 100 mL

omit from the column headed “Claimed Price”:          4.41        substitute:             4.83

[4] Schedule 1, entry for Cephalexin in the form Granules for oral suspension 250 mg per 5 mL, 100 mL

omit from the column headed “Claimed Price”:          5.96        substitute:             6.74

[5]Schedule 1, entry for Ipratropium in the form Nebuliser solution containing ipratropium bromide 250 micrograms (anhydrous) in 1 mL single dose units, 30

omit from the column headed “Claimed Price”:          8.91        substitute:             8.94

[6]Schedule 1, entry for Ipratropium in the form Nebuliser solution containing ipratropium bromide 500 micrograms (anhydrous) in 1 mL single dose units, 30

omit from the column headed “Claimed Price”:          10.48     substitute:             10.52

[7]Schedule 1, entry for Lansoprazole in the form Tablet 15 mg (orally disintegrating)

omit from the column headed “Claimed Price”:          9.12        substitute:             11.88

[8] Schedule 1, entry for Lansoprazole in the form Tablet 30 mg (orally disintegrating)

omit from the column headed “Claimed Price”:          13.42     substitute:             16.17

[9] Schedule 1, entry for Sertraline in each of the forms: Tablet 50 mg (as hydrochloride); and Tablet 100 mg (as hydrochloride)

omit from the column headed “Claimed Price”:          6.27        substitute:             8.22

1. Schedule 1, entry for Sumatriptan in the form Tablet 50 mg (as succinate) [Pricing Quantity/Pack Quantity: 2]

omit from the column headed “Claimed Price”:          4.05        substitute:             4.87

1. Schedule 1, entry for Sumatriptan in the form Tablet (fast disintegrating) 50 mg (as succinate)

omit from the column headed “Claimed Price”:          4.05        substitute:             4.87

1. Schedule 1, after entry for Tamoxifen

insert:

Telmisartan	Tablet 40 mg	Oral	Micardis	28	3.75	5.25
Tablet 80 mg	Oral	Micardis	28	10.86	12.36
Telmisartan with amlodipine	Tablet 40 mg-5 mg (as besylate)	Oral	Twynsta	28	6.84	8.34
Tablet 40 mg-10 mg (as besylate)	Oral	Twynsta	28	8.01	9.51
Tablet 80 mg-5 mg (as besylate)	Oral	Twynsta	28	16.85	18.35
Tablet 80 mg-10 mg (as besylate)	Oral	Twynsta	28	18.02	19.52
Telmisartan with hydrochlorothiazide	Tablet 40 mg-12.5 mg	Oral	Micardis Plus 40/12.5	28	5.25	6.75
Tablet 80 mg-12.5 mg	Oral	Micardis Plus 80/12.5	28	13.12	14.62
Tablet 80 mg-25 mg	Oral	Micardis Plus 80/25	28	14.23	15.73